Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent.~* Over 18 years of age.~* Mean i-STAT potassium values between 5.0 - 6.5 mmol/l inclusive, at screening (Study Day 0).~* Ability to have repeated blood draws or effective venous catheterization.~* Women of childbearing potential must be practicing a highly effective method of birth control.~Exclusion Criteria:~* Pseudohyperkalemia signs and symptoms, such as excessive fist clinching hemolyzed blood specimen, severe leukocytosis or thrombocytosis.~* Subjects treated with lactulose, xifaxan or other nonabsorbed antibiotics for hyperammonemia within the last 7 days.~* Subjects treated with resins (such as Sevelamer acetate or Sodium polystyrene sulfonate \[SPS; e.g. Kayexalate®\]), calcium acetate, calcium carbonate, or lanthanum carbonate, within the last 7 days.~* Subjects with a life expectancy of less than 3 months.~* Subjects who are HIV positive.~* Subjects who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol.~* Women who are pregnant, lactating, or planning to become pregnant.~* Subjects with Ketoacidosis/Acidemia.~* Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.~* Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.~* Previous treatment with ZS~* Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.~* Subjects with cardiac arrhythmias that require immediate treatment.~* Insulin-dependent diabetes mellitus~* Subjects on dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zirconium silicate (acute phase) (Type: EXPERIMENTAL): Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
- Placebo (acute phase) (Type: PLACEBO_COMPARATOR): Placebo ( silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals.
- Zirconium silicate (subacute phase) (Type: EXPERIMENTAL): Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
- Placebo (subacute phase) (Type: PLACEBO_COMPARATOR): Placebo (silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered once a day (qd) prior to the morning meal for 12 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).